What Is SCIG CIDP?
SCIG CIDP refers to the use of subcutaneous immunoglobulin (SCIG) therapy for treating chronic inflammatory demyelinating polyneuropathy (CIDP)—a rare autoimmune neurological disorder. CIDP affects the peripheral nerves, causing weakness, numbness, and impaired motor function. SCIG is an alternative to intravenous immunoglobulin (IVIG), allowing patients to receive treatment under the skin at home.
How SCIG Works for CIDP
SCIG therapy involves regular infusions of immunoglobulin into the fatty tissue beneath the skin. It helps reduce the immune system’s attack on the nerves, slowing disease progression and improving function. SCIG offers a steady and consistent immune response, which may reduce relapses in CIDP patients.
Benefits of SCIG for CIDP
-
Home-based treatment: Reduces hospital visits and increases independence.
-
Fewer systemic side effects: Compared to IVIG, SCIG is often better tolerated.
-
Flexible scheduling: Patients can administer doses weekly or bi-weekly based on medical advice.
-
Improved quality of life: Consistent symptom control without the need for IV access.
Considerations Before Starting SCIG
SCIG may not be suitable for everyone. Factors such as age, comorbidities, and previous response to immunoglobulin therapy should be discussed with a neurologist. Training on self-administration is crucial for safety and efficacy.
For more on CIDP treatment options, visit the GBS|CIDP Foundation International.
Internal Link Suggestions (examples):
Image Alt Text Example:
“Patient self-administering SCIG CIDP treatment at home.”